These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34203177)

  • 21. Yield of Lynch Syndrome Surveillance for Patients With Pathogenic Variants in DNA Mismatch Repair Genes.
    Goverde A; Eikenboom EL; Viskil EL; Bruno MJ; Doukas M; Dinjens WNM; Dubbink EJ; van den Ouweland AMW; Hofstra RMW; Wagner A; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1112-1120.e1. PubMed ID: 31470178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.
    Valentin MD; da Silva FC; dos Santos EM; Lisboa BG; de Oliveira LP; Ferreira Fde O; Gomy I; Nakagawa WT; Aguiar Junior S; Redal M; Vaccaro C; Valle AD; Sarroca C; Carraro DM; Rossi BM
    Fam Cancer; 2011 Dec; 10(4):641-7. PubMed ID: 21681552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genetic analysis of 45 patients with suspected Lynch syndrome using next-generation sequencing].
    Yao ZG; Cheng XK; Lin CH; Li J; Lyu BB; Li JM; Jing HY; Qin YJ; Sun XC
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):843-849. PubMed ID: 34407589
    [No Abstract]   [Full Text] [Related]  

  • 24. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
    Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
    J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
    Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
    JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The MSH2 c.793-1G>A variant disrupts normal splicing and is associated with Lynch syndrome.
    Li Y; Yu L; Cui J; Yin J; Wu W
    Front Oncol; 2023; 13():1131011. PubMed ID: 37538120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classification of MSH6 Variants of Uncertain Significance Using Functional Assays.
    Frederiksen JH; Jensen SB; Tümer Z; Hansen TVO
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
    Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence.
    Moufid FZ; Bouguenouch L; El Bouchikhi I; Chbani L; Iraqui Houssaini M; Sekal M; Belhassan K; Bennani B; Ouldim K
    Genet Test Mol Biomarkers; 2018 Aug; 22(8):492-497. PubMed ID: 30044143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for breast cancer as an integral part of Lynch syndrome.
    Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
    Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal cancer incidence in
    Seppälä T; Pylvänäinen K; Evans DG; Järvinen H; Renkonen-Sinisalo L; Bernstein I; Holinski-Feder E; Sala P; Lindblom A; Macrae F; Blanco I; Sijmons R; Jeffries J; Vasen H; Burn J; Nakken S; Hovig E; Rødland EA; Tharmaratnam K; de Vos Tot Nederveen Cappel WH; Hill J; Wijnen J; Jenkins M; Genuardi M; Green K; Lalloo F; Sunde L; Mints M; Bertario L; Pineda M; Navarro M; Morak M; Frayling IM; Plazzer JP; Sampson JR; Capella G; Möslein G; Mecklin JP; Møller P;
    Hered Cancer Clin Pract; 2017; 15():18. PubMed ID: 29046738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.
    Kempers MJ; Kuiper RP; Ockeloen CW; Chappuis PO; Hutter P; Rahner N; Schackert HK; Steinke V; Holinski-Feder E; Morak M; Kloor M; Büttner R; Verwiel ET; van Krieken JH; Nagtegaal ID; Goossens M; van der Post RS; Niessen RC; Sijmons RH; Kluijt I; Hogervorst FB; Leter EM; Gille JJ; Aalfs CM; Redeker EJ; Hes FJ; Tops CM; van Nesselrooij BP; van Gijn ME; Gómez García EB; Eccles DM; Bunyan DJ; Syngal S; Stoffel EM; Culver JO; Palomares MR; Graham T; Velsher L; Papp J; Oláh E; Chan TL; Leung SY; van Kessel AG; Kiemeney LA; Hoogerbrugge N; Ligtenberg MJ
    Lancet Oncol; 2011 Jan; 12(1):49-55. PubMed ID: 21145788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in Lynch syndrome.
    Li X; Liu G; Wu W
    Exp Hematol Oncol; 2021 Jun; 10(1):37. PubMed ID: 34118983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.
    Pagenstecher C; Wehner M; Friedl W; Rahner N; Aretz S; Friedrichs N; Sengteller M; Henn W; Buettner R; Propping P; Mangold E
    Hum Genet; 2006 Mar; 119(1-2):9-22. PubMed ID: 16341550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification and genetic counselling for a novel splicing mutation of the
    Wang LL; Zou SM; Dong L; Yang M; Qi D; Lu Z; Chen JN; Mei SW; Zhao ZX; Guan X; Jiang Z; Liu Q; Liu Z; Wang XS
    Gastroenterol Rep (Oxf); 2021 Dec; 9(6):552-559. PubMed ID: 34925852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrum and Frequency of Tumors, Cancer Risk and Survival in Chilean Families with Lynch Syndrome: Experience of the Implementation of a Registry.
    Álvarez K; Orellana P; De la Fuente M; Canales T; Pinto E; Heine C; Solar B; Hurtado C; Møller P; Kronberg U; Zarate AJ; Dominguez-Valentin M; López-Köstner F
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour characteristics provide evidence for germline mismatch repair missense variant pathogenicity.
    Li S; Qian D; Thompson BA; Gutierrez S; Wu S; Pesaran T; LaDuca H; Lu HM; Chao EC; Black MH
    J Med Genet; 2020 Jan; 57(1):62-69. PubMed ID: 31391288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
    van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
    J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.